NFE2L2 and colorectal cancer: To this end, we designed a nuclear-targeting sonosensitizer based on the TAT peptide coupled IR780 (TAT-IR780) to load Nrf2-siRNA with the hopes of achieving gene-augmented nuclear-targeting SDT against colorectal cancer and further boosting peptide-based anti-PD-L1 therapy against colorectal metastasis.